Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business OfficerGlobeNewsWire • 03/22/22
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive EsophagitisGlobeNewsWire • 03/14/22
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business ProgressGlobeNewsWire • 03/01/22
Phathom Pharma's Digestive Disease Candidate Meets Primary Goal In Mid-Stage StudyBenzinga • 02/10/22
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)GlobeNewsWire • 02/09/22
Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/23/21
Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare ConferencesGlobeNewsWire • 11/12/21
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business UpdatesGlobeNewsWire • 11/08/21
Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common StockGlobeNewsWire • 10/26/21
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific MeetingGlobeNewsWire • 10/24/21
Phathom's Vonoprazan Non-Inferior To Proton Pump Inhibitor For Esophagitis InflammationBenzinga • 10/18/21
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis TrialGlobeNewsWire • 10/18/21
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)GlobeNewsWire • 09/27/21
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules CapitalGlobeNewsWire • 09/20/21
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori InfectionGlobeNewsWire • 09/08/21
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare ConferenceGlobeNewsWire • 08/31/21
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory MilestonesGlobeNewsWire • 08/10/21
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.GlobeNewsWire • 08/05/21
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GIGlobeNewsWire • 08/02/21
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/25/21
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business UpdatesGlobeNewsWire • 05/11/21
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare ConferenceGlobeNewsWire • 05/06/21